Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY22 results · Oct–Dec 2021
Aarti Drugs reported revenue from operations of ₹634.80 crore (up 19.7% from Q3 FY21) and net profit of ₹58.28 crore (down 14.3% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 634.80 | 530.25 | +19.7% | 579.62 | +9.5% |
| Other income | 6.66 | 2.00 | +233.0% | 0.08 | 83x |
| Total income | 641.46 | 532.25 | +20.5% | 579.70 | +10.7% |
| Profit before tax | 78.69 | 90.37 | −12.9% | 56.08 | +40.3% |
| Net profit for the period | 58.28 | 68.03 | −14.3% | 42.58 | +36.9% |
| Attributable to shareholders of the company | 58.29 | 68.04 | −14.3% | 42.59 | +36.9% |
| EPS, basic (₹) | 6.29 | 7.30 | −13.8% | 4.60 | +36.7% |
| Net margin (%) | 9.2 | 12.8 | 7.3 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 593.21 | 472.10 | +25.7% | 510.70 | +16.2% |
| Other income | 1.62 | 4.07 | −60.2% | 0.89 | +82.0% |
| Total income | 594.83 | 476.17 | +24.9% | 511.59 | +16.3% |
| Profit before tax | 75.35 | 85.16 | −11.5% | 53.11 | +41.9% |
| Net profit for the period | 55.85 | 64.66 | −13.6% | 40.61 | +37.5% |
| EPS, basic (₹) | 6.03 | 6.94 | −13.1% | 4.39 | +37.4% |
| Net margin (%) | 9.4 | 13.7 | 8.0 |
Consolidated
- Filed with BSE
- 01 Feb 2022, 13:59 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2022, 13:59 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Audited
- Source
- XBRL filing on BSE